ACXP Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
2.6M
+14.1%
2.3M
+34.5%
1.7M
+6.1%
1.6M
-20.3%
2.0M
R&D
1.1M
+4.2%
1.1M
+213.8%
341.5K
+21.2%
281.8K
-34.4%
429.7K
SG&A
1.5M
+22.6%
1.2M
-10.1%
1.4M
+2.9%
1.3M
-16.5%
1.6M
Operating Income
-2631739
-14.1%
-2307228
-34.5%
-1715990
-6.1%
-1617116
+20.3%
-2028701
EBITDA
-2631739
-14.1%
-2307228
-34.5%
-1715990
-6.1%
-1617116
+20.3%
-2028701
Net Income
-2583572
-14.6%
-2254173
-34.1%
-1680982
-6.5%
-1578276
+20.8%
-1992790
EPS (Basic)
$-0.49
+7.5%
$-0.53
+14.5%
$-0.62
+13.9%
$-0.72
+41.5%
$-1.23
EPS (Diluted)
$-0.49
+7.5%
$-0.53
+14.5%
$-0.62
+13.9%
$-0.72
+41.5%
$-1.23
Shares (Diluted)
5.3M
+24.8%
4.3M
+56.7%
2.7M
+24.9%
2.2M
+33.9%
1.6M
Acurx Pharmaceuticals (ACXP) — Financials